Literature DB >> 29537617

Nasopharyngeal biopsy in adults presenting with serous otitis media: Cross-sectional study.

Shahaf Shilo1, Sara Abu-Ghanem1, Moshe Yehuda1, Anat Weinger1, Dan M Fliss1, Avraham Abergel1.   

Abstract

BACKGROUND: The purpose of this study was to investigate the association between isolated serous otitis media (SOM) and/or conductive hearing loss (CHL) and nasopharyngeal carcinoma (NPC) in a low-to-intermediate endemic area.
METHODS: Medical records of all adult patients (≥17 years) with SOM/CHL who underwent endoscopic-guided nasopharyngeal biopsy to exclude NPC during a 10-year period were reviewed. Statistical analyses were conducted to identify significant predictors for NPC.
RESULTS: A total of 195 patients were included (121/195; 62.1% men), among whom 169 (86.7%) presented with isolated SOM/CHL. Overall, 12 patients were diagnosed with NPC (12/195; 6.2%), however, only 1 patient (1/169; 0.6%) had isolated SOM/CHL. Coexisting clinical manifestations and suspicious nasopharyngeal findings on fiber-optic nasopharyngoscopy were found to be significant predictors for NPC on univariate and multivariate analyses (P < .05).
CONCLUSION: Patients with isolated SOM/CHL and without coexisting clinical manifestations or suspicious findings on nasopharyngoscopy may avoid a routine nasopharyngeal biopsy.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  conductive hearing loss; fiber-optic nasopharyngoscopy; nasopharyngeal biopsy; nasopharyngeal carcinoma; serous otitis media

Mesh:

Year:  2018        PMID: 29537617     DOI: 10.1002/hed.25135

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  1 in total

Review 1.  Diagnosis of possible nasopharyngeal malignancy in adults with isolated serous otitis media; a systematic review and proposal of a management algorithm.

Authors:  Max Rohde; Malene Korsholm; Michael Lüscher; Søren Fast; Christian Godballe
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-01-31       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.